Introduction: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematological disease characterized by intravascular hemolysis, thrombosis, and bone marrow (BM) failure. Although PNH is caused by excessive proliferation of hematopoietic stem cell (HSC) clones with loss of function mutations in phosphatidylinositol N-acetylglucosaminyltransferase subunit A () genes, what drives PNH clones to expand remains elusive.

Case Description: We present a case of a 26-year-old female who presented with hemolytic anemia, thrombocytopenia, and leukopenia. Flow cytometry analysis of peripheral blood showed that 71.9% and 15.3% of the granulocytes and erythrocytes were glycosylphosphatidylinositol-anchored protein deficient (GPI[-]) cells. The patient was diagnosed with PNH with non-severe aplastic anemia. Deep-targeted sequencing covering 390 different genes of sorted GPI(-) granulocytes revealed three different mutations (p.I69fs, variant allele frequency (VAF) 24.2%; p.T192P, VAF 5.8%; p.V300fs, VAF 5.1%) and no other mutations. She received six cycles of eculizumab and oral cyclosporine. Although the patient's serum lactate dehydrogenase level decreased, she remained dependent on red blood cell transfusion. Six months after diagnosis, she received a syngeneic bone marrow transplant (BMT) from a genetically identical healthy twin, following an immune ablative conditioning regimen consisting of cyclophosphamide 200 mg/kg and rabbit anti-thymocyte globulin 10 mg/kg. After four years, the patient's blood count remained normal without any signs of hemolysis. However, the peripheral blood still contained 0.2% GPI (-) granulocytes, and the three mutations that had been detected before BMT persisted at similar proportions to those before transplantation (p.I69fs, VAF 36.1%; p.T192P, VAF 3.7%; p.V300fs, VAF 8.6%) in the small PNH clones that persisted after transplantation.

Conclusions: The PNH clones that had increased excessively before BMT decreased, but persisted at low percentages for more than four years after the immunoablative conditioning regimen followed by syngeneic BMT. These findings indicate that as opposed to conventional theory, immune pressure on HSCs, which caused BM failure before BMT, was sufficient for -mutated HSCs to clonally expand to develop PNH.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10822943PMC
http://dx.doi.org/10.3389/fimmu.2023.1329403DOI Listing

Publication Analysis

Top Keywords

pnh clones
12
immune pressure
8
hematopoietic stem
8
paroxysmal nocturnal
8
nocturnal hemoglobinuria
8
bone marrow
8
peripheral blood
8
three mutations
8
pt192p vaf
8
pv300fs vaf
8

Similar Publications

PIGA mutation cannot fully explain the proliferative advantage of abnormal clones and thrombosis tendency in paroxysmal nocturnal haemoglobinuria (PNH), and additional genes may play a role, justifying further investigation. CD59+ and CD59- peripheral blood mononuclear cells from six PNH patients were sorted and subjected to whole-exon sequencing (WES) and whole-transcriptome sequencing respectively. Six age- and sex-matched healthy volunteers were enrolled as controls.

View Article and Find Full Text PDF

Monitoring and Treatment of Paroxysmal Nocturnal Hemoglobinuria in Patients with Aplastic Anemia in Asia: An Expert Consensus.

Int J Mol Sci

November 2024

Cancer Center, Division of Hematology and Oncology, Department of Medicine, Taipei Municipal Wanfang Hospital, Taipei Medical University, No. 111, Section 3, Xinglong Rd, Wenshan District, Taipei City 11696, Taiwan.

Paroxysmal nocturnal hemoglobinuria (PNH) clones can be identified in a significant proportion of patients with aplastic anemia (AA). Screening for PNH clones at the time of an AA diagnosis is recommended by national and international guidelines. In this report, an expert panel of physicians discusses current best practices and provides recommendations for managing PNH in patients with AA in the Asia-Pacific region.

View Article and Find Full Text PDF
Article Synopsis
  • * Results showed stable health markers (LDH, hemoglobin, reticulocytes) throughout the study, with no significant differences in kidney disease rates or need for blood transfusions among patients.
  • * The findings indicate that the biosimilar is both effective and safe for long-term use in PNH patients, with only a low incidence of adverse reactions reported.
View Article and Find Full Text PDF
Article Synopsis
  • FLAER (Fluorescently labeled aerolysin) is used to identify PNH clones in blood samples, but there's limited information on its expression in normal bone marrow cells.
  • This study analyzed 54 bone marrow samples from various conditions, including PNH and different types of leukemia, to understand FLAER expression in both normal and diseased hematopoiesis.
  • Results showed that while FLAER intensity was generally intermediate in stem cells, a specific FLAER-negative subgroup was found in PNH patients, indicating varying expression levels in myeloid precursors across different conditions.
View Article and Find Full Text PDF
Article Synopsis
  • * Immunosuppressive therapies (IST) are particularly beneficial for patients with lower-risk MDS, especially those with certain bone marrow characteristics.
  • * Accurately diagnosing lower-risk MDS can be challenging and requires careful evaluation of the bone marrow, with IST recommended as the first-line treatment for those showing signs of immune-related bone marrow failure.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!